US Stock Market Move | Announcement of strong data for the next generation weight-loss candidate drug, Novo Nordisk A/S Sponsored ADR Class B (NVO.US), surged more than 2.9% against the market trend.

On Tuesday, Novo Nordisk A/S Sponsored ADR Class B (NVO.US) stock price rose against the market trend, as of the time of writing, the stock surged over 2.9% to $46.3. On the news front, the company stated that its next-generation weight loss and diabetes candidate drug amycretin showed significant therapeutic effects in the latest study, effectively lowering patients' blood sugar and achieving significant weight loss, bringing a first-line positive for this pressure-bearing pharmaceutical company in the weight loss market competition. The study showed that patients injected with amycretin once a week experienced an average weight loss of up to 14.5% within 36 weeks; if taken orally once a day, patients also experienced an average weight loss of 10.1%. Novo Nordisk A/S Sponsored ADR Class B stated that this is a key achievement in the company's layout of next-generation metabolic drugs. Analyst Michael Shah mentioned that in terms of weight loss effects, amycretin outperforms Zepbound under Lilly's (LLY.US) and the next-generation oral drug orforglipron, but due to different trial designs, the two are difficult to compare directly; Additionally, the participants in the Novo Nordisk A/S Sponsored ADR Class B trial were overall heavier, and those with higher weight were more likely to experience larger weight loss in the early stages.